FDA 执法报告 D-0083-2027 将 Par Health USA 的 Argatroban 注射液颗粒物召回定为 Class I
FDA drug enforcement D-0083-2027: Par Health USA, LLC — Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
FDA 执法报告 D-0083-2027 将 Par Health USA 的 Argatroban 注射液 250 mg/2.5mL 因颗粒物的召回定为 Class I,涉及批次 84193(效期 10/2026)与 92880(效期 08/2027),共 1944 瓶。
记录列出该注射剂因颗粒物召回的等级、批号与全美分销范围,可作为同类颗粒污染调查的对照样本。
FDA 药品召回执法报告 — D-0083-2027
报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。
完整官方产品记录(含 openFDA 统一标识符):
{
"address_1": "870 Parkdale Rd",
"address_2": "",
"center_classification_date": "20261026",
"city": "Rochester",
"classification": "Class I",
"code_info": "Lot #: 84193, Exp Date: 10/2026; 92880, Exp Date: 08/2027.",
"country": "United States",
"distribution_pattern": "Nationwide within the United States",
"event_id": "100072",
"initial_firm_notification": "Press Release",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA091665"
],
"brand_name": [
"ARGATROBAN"
],
"generic_name": [
"ARGATROBAN"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Par Health USA, LLC"
],
"nui": [
"N0000175980",
"N0000175518",
"N0000009963"
],
"package_ndc": [
"42023-182-89"
],
"pharm_class_epc": [
"Anti-coagulant [EPC]",
"Direct Thrombin Inhibitor [EPC]"
],
"pharm_class_moa": [
"Thrombin Inhibitors [MoA]"
],
"product_ndc": [
"42023-182"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"INTRAVENOUS"
],
"rxcui": [
"308351"
],
"spl_id": [
"493ddc78-4566-486f-8cdd-7d6868ddf153"
],
"spl_set_id": [
"1a67a87d-59cb-414c-a11e-ab8f0a9bb778"
],
"substance_name": [
"ARGATROBAN"
],
"unii": [
"IY90U61Z3S"
]
},
"postal_code": "48307-1740",
"product_description": "Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/ Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Cranbury, NJ 08512, NDC 42023-182-89.",
"product_quantity": "1944 vials",
"product_type": "Drugs",
"reason_for_recall": "Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.",
"recall_initiation_date": "20261013",
"recall_number": "D-0083-2027",
"recalling_firm": "Par Health USA, LLC",
"report_date": "20261028",
"state": "MI",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov